A Phase 3 interventional study of Cefepime/VNRX-5133 (taniborbactam) and Meropenem in Urinary Tract Infections and Acute Pyelonephritis, sponsored by Venatorx Pharmaceuticals, Inc.. Completed at 78 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.
Sponsored by Venatorx Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Urinary Tract Infections with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Urinary Tract Infections · China.
Among the 26 studies in Urinary Tract Infections with a site in China, this one is the 2nd largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 3, and was the 6th registered.
804 studies on the registry are indexed under Urinary Tract Infections; 134 are open to participants now.
Browse Urinary Tract Infections studies →6 of the 26 studies in Urinary Tract Infections with a site in China are open now. Recruiting first, the newest first:
Joincare Pharmaceutical Group Industry Co., Ltd · Sites in China
Ages 18–45 · Healthy volunteers
Zhangzhou Municipal Hospital · Sites in China
Ages 14–85
Zensun Sci. & Tech. Co., Ltd. · Sites in China
Ages 18–75
Zhuhai United Laboratories Co., Ltd. · Sites in China
Ages 18–45 · Healthy volunteers
Yanjun Zhang, Baoyan Liu · Sites in China
Ages 18–75 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 24 (29%) stop at 75 or younger; 16 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 8 · Phase 4 2
First in 2009; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 661 is above the median of 133 across 562 interventional studies indexed under Urinary Tract Infections.
Median enrollment 150 across the 22 interventional studies, 219 across the 4 observational. Of the 17 that completed or were terminated, 4 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 26 have an industry lead sponsor. The 10 most frequent:
Venatorx Pharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Venatorx Pharmaceuticals, Inc. has 1 study filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Urinary Tract Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07719257Zhuhai United Laboratories Co., Ltd.Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD) | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Urinary Tract Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.
Drug: Cefepime/VNRX-5133 (taniborbactam)
Meropenem will be administered q8h IV over 30 minutes.
Drug: Meropenem
Drug page: Taniborbactam
Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Microbiologic Success at Test of Cure (TOC) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Clinical Success at Test of Cure (TOC) in the microITT Population
Symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Composite Success at Test of Cure (TOC) in the Extended Microbiological Intent-to-treat (emicroITT) Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Composite Success at End of Treatment (EOT) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Microbiological Success at End of Treatment (EOT) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Clinical Success at End of Treatment (EOT) in the microITT Population
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Composite Success at Late Follow Up (LFU) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Microbiological Success at Late Follow Up (LFU) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Clinical Success at Late Follow Up (LFU) in the microITT Population
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Investigator Opinion of Clinical Success at Test of Cure (TOC) in the microITT Population
The proportion of patients with clinical success based on investigator opinion at TOC.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Composite Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Clinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Composite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Clinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Composite Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Clinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Composite Success at End of Treatment (EOT) in the Microbiologically-Evaluable (ME) Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Microbiologic Success at End of Treatment (EOT) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Composite Success at Test of Cure (TOC) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Microbiologic Success at Test of Cure (TOC) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Composite Success at Late Follow Up (LFU) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Microbiologic Success at Late Follow Up (LFU) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Composite Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at the End of Treatment (EOT) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Composite Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Microbiologic Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Composite Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Microbiologic Success in Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Clinical Success at End of Treatment (EOT) in the Clinically Evaluable (CE) Population
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Clinical Success at Test of Cure (TOC) in the CE Population
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Clinical Success at Late Follow Up (LFU) in the CE Population
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Clinical Success in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the CE Population
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Clinical Success in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the CE Population
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Clinical Success in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the CE Population
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Per-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the microITT Population
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Per-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the microITT Population
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Per-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the microITT Population
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the microITT Population
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure (TOC) in the microITT Population
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the microITT Population
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Per-Pathogen Microbiologic Eradication at End of Treatment (EOT) in the ME Population
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Per-Pathogen Microbiologic Eradication at Test of Cure (TOC) in the ME Population
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Per-Pathogen Microbiologic Eradication at Late Follow Up (LFU) in the ME Population
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at End of Treatment (EOT) in the ME Population
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed within 24 hours after last IV dose (up to 15 days from start of treatment)
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Test of Cure TOC in the ME Population
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Per-Pathogen Microbiologic Eradication in Patients With Cefepime-Resistant Pathogens at Late Follow Up (LFU) in the ME Population
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
Time frame: Assessed at Late Follow Up visit (occurred once per participant between Study Days 28 to 35)
Number of Patients With Treatment-Emergent Adverse Events
Percent of participants experiencing Treatment Emergent Adverse Events (TEAE). Treatment emergent is defined as any event that starts or worsens during or after treatment.
Time frame: Study Days 1 to 35
Number of Patients With Serious Adverse Events
Percent of participants experiencing treatment emergent Serious Adverse Events (SAE).
Time frame: Study Days 1 to 35
Six-hundred sixty-one (661) male and female patients with complicated urinary tract infection (cUTI) including acute pyelonephritis (AP), were randomized into 2 groups (cefepime - VNRX-5133, and meropenem) at 68 hospital sites in North and South America, Eastern Europe, and China, from August 2019 until the last patient's final visit in December 2021. Of these 661 patients in the intent-to-treat (ITT) population, 436 were in the MicroITT population (293 cefepime - VNRX-5133, 143 meropenem).
| Milestone | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Started | 441 | 220 |
| Completed | 414 | 212 |
| Not completed | 27 | 8 |
| Withdrew: Adverse event | 13 | 2 |
| Withdrew: Withdrawal by subject | 8 | 2 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Randomized but not treated, iwrs issue, lack of imp supplies. | 1 | 4 |
| Milestone | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Started | 441 | 220 |
| Completed | 426 | 214 |
| Not completed | 15 | 6 |
| Withdrew: Withdrawal by subject | 6 | 2 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Covid-19 related | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Iwrs issue, patient refused, sae, randomized in error, patient did not take imp or attend visits. | 3 | 3 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population | 207 | 83 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Microbiologic Success at Test of Cure (TOC) in the microITT Population | 229 | 95 |
Symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Clinical Success at Test of Cure (TOC) in the microITT Population | 251 | 116 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Composite Success at Test of Cure (TOC) in the Extended Microbiological Intent-to-treat (emicroITT) Population | 216 | 86 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Composite Success at End of Treatment (EOT) in the microITT Population | 261 | 123 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Microbiological Success at End of Treatment (EOT) in the microITT Population | 284 | 139 |
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Clinical Success at End of Treatment (EOT) in the microITT Population | 265 | 127 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Composite Success at Late Follow Up (LFU) in the microITT Population | 187 | 74 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Microbiological Success at Late Follow Up (LFU) in the microITT Population | 207 | 90 |
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Clinical Success at Late Follow Up (LFU) in the microITT Population | 238 | 102 |
The proportion of patients with clinical success based on investigator opinion at TOC.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Investigator Opinion of Clinical Success at Test of Cure (TOC) in the microITT Population | 271 | 128 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 57 | 26 |
| Cefepime-resistant Pseudomonas aeruginosa | 1 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 65 | 28 |
| Cefepime-resistant Pseudomonas aeruginosa | 1 | — |
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacterales | 57 | 28 |
| Pseudomonas aeruginosa | 1 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 47 | 16 |
| Cefepime-resistant Pseudomonas aeruginosa | 0 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 50 | 18 |
| Cefepime-resistant Pseudomonas aeruginosa | 0 | — |
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterbacterales | 54 | 25 |
| Pseudomonas aeruginosa | 0 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 45 | 13 |
| Cefepime-resistant Pseudomonas aeruginosa | 0 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 48 | 16 |
| Cefepime-resistant Pseudomonas aeruginosa | 0 | — |
Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacterales | 49 | 20 |
| Pseudomonas aeruginosa | 0 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Composite Success at End of Treatment (EOT) in the Microbiologically-Evaluable (ME) Population | 259 | 121 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Microbiologic Success at End of Treatment (EOT) in the ME Population | 279 | 137 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Composite Success at Test of Cure (TOC) in the ME Population | 195 | 76 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Microbiologic Success at Test of Cure (TOC) in the ME Population | 214 | 88 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Composite Success at Late Follow Up (LFU) in the ME Population | 178 | 69 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Microbiologic Success at Late Follow Up (LFU) in the ME Population | 192 | 84 |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 56 | 26 |
| Cefepime-resistant Pseudomonas aeruginosa | 1 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 62 | 28 |
| Cefepime-resistant Pseudomonas aeruginosa | 1 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 44 | 12 |
| Cefepime-resistant Pseudomonas aeruginosa | 0 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 46 | 14 |
| Cefepime-resistant Pseudomonas aeruginosa | 0 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL. Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 44 | 11 |
| Cefepime-resistant Pseudomonas aeruginosa | 0 | — |
Microbiologic success is eradication defined as demonstration that any gram-negative bacterial pathogen found at study entry (≥10\^5 CFU/mL) is eradicated to \<10\^3 CFU/mL.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Cefepime-resistant Enterobacterales | 45 | 14 |
| Cefepime-resistant Pseudomonas aeruginosa | 0 | — |
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Clinical Success at End of Treatment (EOT) in the Clinically Evaluable (CE) Population | 384 | 187 |
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Clinical Success at Test of Cure (TOC) in the CE Population | 343 | 162 |
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Clinical Success at Late Follow Up (LFU) in the CE Population | 321 | 142 |
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacterales | 63 | 31 |
| Pseudomonas aeruginosa | 6 | 2 |
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacterales | 56 | 23 |
| Pseudomonas aeruginosa | 4 | 2 |
Symptomatic clinical success is defined as symptomatic resolution or return to pre-morbid baseline of all UTI-core symptoms and patient is alive, and patient has not received additional antibacterial therapy for cUTI.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacterales | 52 | 19 |
| Pseudomonas aeruginosa | 3 | 1 |
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| pathogens | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Citrobacter freundii complex | 2 | 2 |
| Citrobacter koseri | 1 | 1 |
| Enterobacter cloacae complex | 14 | 3 |
| Escherichia coli | 197 | 95 |
| Klebsiella aerogenes | 1 | 1 |
| Klebsiella oxytoca | 5 | 1 |
| Klebsiella pneumoniae | 37 | 20 |
| Klebsiella variicola | 1 | 1 |
| Kluyvera ascorbata | 1 | — |
| Morganella morganii | 2 | 2 |
| Proteus hauseri | 1 | — |
| Proteus mirabilis | 10 | 10 |
| Proteus penneri | 1 | — |
| Proteus vulgaris | 2 | — |
| Serratia marcescens | 2 | — |
| Providencia rettgeri | — | 1 |
| Pseudomonas aeruginosa | 11 | 6 |
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| pathogens | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Citrobacter freundii complex | 2 | 2 |
| Citrobacter koseri | 0 | 1 |
| Enterobacter cloacae complex | 12 | 1 |
| Escherichia coli | 165 | 67 |
| Klebsiella aerogenes | 0 | 0 |
| Klebsiella oxytoca | 5 | 1 |
| Klebsiella pneumoniae | 27 | 14 |
| Klebsiella varricola | 1 | 1 |
| Kluyvera ascorbata | 1 | — |
| Morganella morganii | 2 | 2 |
| Proteus hauseri | 0 | — |
| Proteus mirabilis | 9 | 5 |
| Proteus penneri | 1 | — |
| Proteus vulgaris | 1 | — |
| Providencia rettgeri | — | 1 |
| Serratia marcescens | 2 | — |
| Pseudomonas aeruginosa | 5 | 4 |
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| pathogens | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Citrobacter freundii complex | 1 | 2 |
| Citrobacter koseri | 0 | 1 |
| Enterobacter cloacae complex | 12 | 1 |
| Escherichia coli | 141 | 61 |
| Klebsiella aerogenes | 0 | 0 |
| Klebsiella oxytoca | 4 | 1 |
| Klebsiella pneumoniae | 30 | 14 |
| Klebsiella variicola | 1 | 1 |
| Kluyvera ascorbata | 1 | — |
| Morganella morganii | 2 | 2 |
| Proteus hauseri | 0 | — |
| Proteus mirabilis | 8 | 6 |
| Proteus penneri | 1 | — |
| Proteus vulgaris | 2 | — |
| Providencia rettgeri | — | 1 |
| Serratia marcescens | 2 | — |
| Pseudomonas aeruginosa | 5 | 4 |
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| percentage of pathogen eradication | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacter cloacae complex | 100 | 100 |
| Escherichia coli | 100 | 88.9 |
| Klebsiella oxytoca | 100 | — |
| Klebsiella pneumoniae | 95.0 | 100 |
| Morganella morganii | — | 100 |
| Proteus mirabilis | 100 | 100 |
| Pseudomonas aeruginosa | 100 | — |
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| percentage of eradicated pathogens | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacter cloacae complex | 100 | 50.0 |
| Escherichia coli | 81.1 | 61.1 |
| Klebsiella oxytoca | 100 | — |
| Klebsiella pneumoniae | 60.0 | 71.4 |
| Morganella morganii | — | 100 |
| Proteus mirabilis | 50.0 | 0 |
| Pseudomonas aeruginosa | 0 | — |
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| percentage of pathogen eradication | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacter cloacae complex | 100 | 50.0 |
| Escherichia coli | 73.0 | 50.0 |
| Klebsiella oxytoca | 100 | — |
| Klebsiella pneumoniae | 65.0 | 71.4 |
| Morganella morganii | — | 100 |
| Proteus mirabilis | 50.0 | 0 |
| Pseudomonas aeruginosa | 0 | — |
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| pathogens | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Citrobacter freundii complex | 2 | 2 |
| Citrobacter koseri | 1 | 1 |
| Enterobacter cloacae complex | 14 | 3 |
| Escherichia coli | 193 | 94 |
| Klebsiella aerogenes | 1 | 1 |
| Klebsiella oxytoca | 5 | 1 |
| Klebsiella pneumoniae | 37 | 20 |
| Klebsiella variicola | 1 | 1 |
| Kluyvera ascorbata | 1 | — |
| Morganella morganii | 2 | 2 |
| Proteus hauseri | 1 | — |
| Proteus mirabilis | 9 | 9 |
| Proteus penneri | 1 | — |
| Proteus vulgaris | 2 | — |
| Providencia rettgeri | — | 1 |
| Serratia marcescens | 2 | — |
| Pseudomonas aeruginosa | 11 | 6 |
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| pathogens | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Citrobacter freundii complex | 2 | 2 |
| Citrobacter koseri | 0 | 1 |
| Enterobacter cloacae complex | 11 | 0 |
| Escherichia coli | 154 | 64 |
| Klebsiella aerogenes | 0 | 0 |
| Klebsiella oxytoca | 5 | 1 |
| Klebsiella pneumoniae | 26 | 12 |
| Klebsiella variicola | 1 | 1 |
| Kluyvera ascorbata | 1 | — |
| Morganella morganii | 2 | 1 |
| Proteus hauseri | 0 | — |
| Proteus mirabilis | 8 | 5 |
| Proteus penneri | 1 | — |
| Proteus vulgaris | 1 | — |
| Providencia rettgeri | — | 1 |
| Serratia marcescens | 1 | — |
| Pseudomonas aeruginosa | 5 | 4 |
Per-pathogen eradication by baseline gram-negative pathogens. The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| pathogens | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Citrobacter freundii complex | 1 | 2 |
| Citrobacter koseri | — | 1 |
| Enterobacter cloacae complex | 12 | 1 |
| Escherichia coli | 130 | 56 |
| Klebsiella aerogenes | 0 | 0 |
| Klebsiella oxytoca | 3 | 1 |
| Klebsiella pneumoniae | 29 | 14 |
| Klebsiella variicola | 1 | 1 |
| Kluyvera ascorbata | 1 | — |
| Morganella morganii | 2 | 1 |
| Proteus hauseri | 0 | — |
| Proteus mirabilis | 6 | 6 |
| Proteus penneri | 1 | — |
| Proteus vulgaris | 2 | — |
| Providencia rettgeri | — | 1 |
| Serratia marcescens | 2 | — |
| Pseudomonas aeruginosa | 5 | 4 |
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| percentage of pathogen eradication | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacter cloacae complex | 100 | 100 |
| Escherichia coli | 100 | 100 |
| Klebsiella oxytoca | 100 | — |
| Klebsiella pneumoniae | 95.0 | 100 |
| Morganella morganii | — | 100 |
| Proteus mirabilis | 100 | 100 |
| Pseudomonas aeruginosa | 100 | — |
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| percentage of pathogen eradication | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacter cloacae complex | 100 | 0 |
| Escherichia coli | 87.5 | 66.7 |
| Klebsiella oxytoca | 100 | — |
| Klebsiella pneumoniae | 64.7 | 66.7 |
| Proteus mirabilis | 50.0 | 0 |
| Pseudomonas aeruginosa | 0 | — |
Per-pathogen eradication by baseline gram-negative pathogens (only pathogens identified 10 or more times are reported). The number analyzed corresponds to the number of specified pathogens. The number is the percent of the specified pathogen identified at baseline in each treatment group that had been eradicated.
| percentage of pathogen eradication | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Enterobacter cloacae complex | 100 | 50.0 |
| Escherichia coli | 78.1 | 53.3 |
| Klebsiella pneumoniae | 68.4 | 71.4 |
| Proteus mirabilis | 50.0 | 0 |
| Pseudomonas aeruginosa | 0 | — |
Percent of participants experiencing Treatment Emergent Adverse Events (TEAE). Treatment emergent is defined as any event that starts or worsens during or after treatment.
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Number of Patients With Treatment-Emergent Adverse Events | 156 | 63 |
Percent of participants experiencing treatment emergent Serious Adverse Events (SAE).
| Participants | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| Number of Patients With Serious Adverse Events | 9 | 4 |
Collected over From first dose to last follow-up visit (Day 28-35).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cefepime/VNRX-5133 (Taniborbactam) | 1/440 (0.2%) | 9/440 (2%) | 93/440 (21.1%) |
| Meropenem | 0/217 (0%) | 4/217 (1.8%) | 37/217 (17.1%) |
| Event | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| PyelonephritisInfections and infestations | 0/440 | 2/217 |
| Pyelonephritis acuteInfections and infestations | 0/440 | 1/217 |
| Tubo-ovarian abscessInfections and infestations | 0/440 | 1/217 |
| UreterolithiasisRenal and urinary disorders | 0/440 | 1/217 |
| COVID-19Infections and infestations | 2/440 | 0/217 |
| AppendicitisInfections and infestations | 1/440 | 0/217 |
| EndocarditisInfections and infestations | 1/440 | 0/217 |
| Gastrointestinal candidiasisInfections and infestations | 1/440 | 0/217 |
| Renal abscessInfections and infestations | 1/440 | 0/217 |
| Urinary tract infectionInfections and infestations | 1/440 | 0/217 |
| Event | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem |
|---|---|---|
| HeadacheNervous system disorders | 27/440 | 8/217 |
| DiarrhoeaGastrointestinal disorders | 18/440 | 5/217 |
| ConstipationGastrointestinal disorders | 14/440 | 3/217 |
| Alanine aminotransferase increasedInvestigations | 4/440 | 5/217 |
| HypertensionVascular disorders | 9/440 | 2/217 |
| NauseaGastrointestinal disorders | 9/440 | 2/217 |
| Abdominal distensionGastrointestinal disorders | 7/440 | 3/217 |
| DizzinessNervous system disorders | 7/440 | 1/217 |
| HypokalaemiaMetabolism and nutrition disorders | 7/440 | 1/217 |
| AnaemiaBlood and lymphatic system disorders | 6/440 | 3/217 |
Intent-to-treat (ITT) population: all randomized patients
| Age, Continuous(years) | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem | Total |
|---|---|---|---|
| Mean | 56.2 ± 17.43 | 55.8 ± 18.15 | 56.1 ± 17.66 |
| Age, Customized(Participants) | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem | Total |
|---|---|---|---|
| Age Categories (years) — <65 | 275 | 137 | 412 |
| Age Categories (years) — 65 - 75 | 111 | 56 | 167 |
| Age Categories (years) — >75 | 55 | 27 | 82 |
| Sex: Female, Male(Participants) | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem | Total |
|---|---|---|---|
| Female | 248 | 115 | 363 |
| Male | 193 | 105 | 298 |
| Ethnicity (NIH/OMB)(Participants) | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem | Total |
|---|---|---|---|
| Hispanic or Latino | 47 | 20 | 67 |
| Not Hispanic or Latino | 393 | 199 | 592 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Cefepime/VNRX-5133 (Taniborbactam) | Meropenem | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 1 | 5 |
| Asian | 36 | 17 | 53 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 6 |
| White | 386 | 191 | 577 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 12 | 8 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2019 to primary completion in Dec 2021, 28 months.
Results were first posted in May 2024, 2 years 5 months after primary completion. A results delay was requested in Dec 2022.
Of 23 industry-sponsored phase 3 interventional studies under Urinary Tract Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 28 months is above that.
Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Taniborbactam
Venatorx Pharmaceuticals, Inc.